- Home
- RYN vs ARQT Comparison
RYN vs ARQT Comparison
Compare RYN & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RYN | ARQT |
|---|---|---|
| Founded | 1926 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.3B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | RYN | ARQT |
|---|---|---|
| Price | $22.83 | $25.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $27.00 | $25.00 |
| AVG Volume (30 Days) | ★ 3.0M | 1.5M |
| Earning Date | 02-11-2026 | 02-25-2026 |
| Dividend Yield | ★ 12.71% | N/A |
| EPS Growth | ★ 373.89 | N/A |
| EPS | ★ 5.07 | N/A |
| Revenue | ★ $1,293,371,000.00 | $317,929,000.00 |
| Revenue This Year | N/A | $85.83 |
| Revenue Next Year | N/A | $30.72 |
| P/E Ratio | $8.90 | ★ N/A |
| Revenue Growth | 60.70 | ★ 129.21 |
| 52 Week Low | $21.06 | $11.13 |
| 52 Week High | $28.31 | $31.77 |
Technical Indicators
Market Signals| Indicator | RYN | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 48.09 | 37.28 |
| Support Level | $22.93 | $25.51 |
| Resistance Level | $24.01 | $26.97 |
| Average True Range (ATR) | 0.70 | 1.08 |
| MACD | -0.17 | -0.15 |
| Stochastic Oscillator | 30.31 | 12.10 |
Price Performance
Historical ComparisonAbout RYN Rayonier Inc. REIT
Rayonier owns and manages over 2 million acres of timberland in the United States. It is one the largest private landowners in North America. Rayonier is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.